DECLARATION FOR "371" APPLICATION Page 1 of 2

COMBINED DECLARA			ATTORNEY'S DOCKET PR60446USw
APPLICATION WITH P	OWER OF ATTORNE	Y	First Names Inventor:
			BACUS
() Deplemention out with a divide in intel 611			Complete if known:
() Declaration submitted with initial fili	App No.:		
() Declaration submitted after initial fili	ng (surcharge required 37CFR1.16(e))		ET. D
			Filing Date
			Group Art Unit:
As below named inv	ventor. I hereby declare that:		
My residence, post office add	lress and citizenship are as stated b	elow next to my name.	
I believe I am the original, fir (if plural names are listed bel entitled:	rst and sole inventor (if only one nation) of the subject matter which is	ame is listed below) or an original, claimed and for which a patent is s	first and joint inventor sought on the invention
	BIOMARKERS I	N CANCER	
the specification of which (ch		AV CIMICEN	·
[]is attached hereto. OR			
[x] was filed on	as United States application	Serial No or PCT	International
	IS2004/026434 filed <u>August 10, 20</u> licable)	004 and was amended on (MM/DD	/YYYY)
I hereby state that I have revi as amended by any amendme	iewed and understand the contents ent specifically referred to above.	of the above-identified specificatio	n, including the claims,
I acknowledge the duty to dis	sclose information which is materia	d to patentability as defined in 37 (CFR §1.56.
I hereby claim foreign priority benefit inventor's certificate or 365(a) of any States of America, listed below and ha inventor's certificate or of any PCT in claimed:	PCT international application which are also identified below, by checking ternational application having a file	ch designated at least one country ong the box, any foreign application ing date before that of the applicat	other than the United n for patent or
PRIOR FOREIGN AND ANY PRICE			
Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY))	PRIORITY CLAIMED
1.			
2.			
3. 4.			
5.			
I hereby claim the benefit under Title	35. United States Code 8119(e) of	any United States provisional anni	ication(s) listed below:
Application No.		te (MM/DD/YYYY)	iondon(b) fision Uciuw.
1. 60/495,325		08/15/2003	
2			
3.			

DECLARATION FOR "371" APPLICATION Page 2 of 2

COMBINED DECLARATION FOR UTILITY or DESIGN
PATENT APPLICATION WITH POWER OF ATTORNEY

ATTORNEY'S DOCKET NUMBER PR60446USW

Continued

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. PARENT APPLICATION	or PCT PARENT APPLICAT	TON				
			STATUS (Check one)			
U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	PATENTED	PENDING	ABANDONED		
POWER OF ATTORNEY: As a named inverprosecute this application and to transact all but Customer Number 23347 and Customer Number	siness in the Patent and Trademar	ners associated with the k Office connected ther	e Customer Number rewith	rs provided below to		
Address all correspondence and telephone calls to Customer Number 23347 David J. Levy Corporate Intellectual Property GlaxoSmithKline				lls to: ia Campen 483-1012		
Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 L howely dealers that all statements made he						

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	FULL NAME	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL	
.2	OF INVENTOR	BACUS	Sarah	S	
	INVENTOR'S	Signature		Date:	
	SIGNATURE				
0	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	CITIZENSHIP	Hinsesdale	IL	US	
	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
1	ADDRESS	1222 Indian Trail	Hinsdale	Illinois 27709, US	
	FULL NAME	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL	
2	OF INVENTOR	SPECTOR	Neil/	Lee	
ł	INVENTOR'S	Signature	7	Date: O / /	
	SIGNATURE	July XI	<u>- </u>	7/1/04	
0	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	CITIZENSHIP	Durham	NC	US	
1	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
2	ADDRESS	GlaxoSmithKline	Research Triangle Park	North Carolina 27709, US	
		Five Moore Drive, PO Box 13398			

DECLARATION FOR "371" APPLICATION Page 1 of 2

COMBINED DECLAR APPLICATION WITH	ATTORNEY'S DOCKET PR60446USw First Names Inventor: BACUS					
() Declaration submitted with initial () Declaration submitted after initial	J	quired 37CFR1.16(e))		Complete if known: App No.: Filing Date Group Art Unit:		
As below named	inventor. I herel	by declare that:				
My residence, post office	address and citize	enship are as stated belo	w next to my name.			
I believe I am the original (if plural names are listed entitled:	, first and sole in below) of the sub	ventor (if only one name oject matter which is cla	is listed below) or an original, fimed and for which a patent is so	irst and joint inventor ought on the invention		
the specification of which	(check only one	BIOMARKERS IN item below):	CANCER			
[]is attached hereto. OR						
[x] was filed on	as Unit	ed States application Ser	rial No or PCT	International		
	<u>r/US2004/02643</u> applicable)	4 filed <u>August 10, 2004</u>	and was amended on (MM/DD	/YYYY)		
I hereby state that I have a as amended by any amend			he above-identified specification	n, including the claims,		
I acknowledge the duty to	disclose informa	ntion which is material to	patentability as defined in 37 C	CFR §1.56.		
I hereby claim foreign priority ben inventor's certificate or 365(a) of a States of America, listed below and certificate or of any PCT internation PRIOR FOREIGN AND ANY P	ny PCT internati d have also identi onal application h	onal application which d ified below, by checking laving a filing date befor	lesignated at least one country of the box, any foreign application that of the application on which	ther than the United n for patent or inventor's		
Prior Foreign Application Number (s)		Country	Foreign Filing Date (MM/DD/YYYY))	PRIORITY CLAIMED		
1.			(1411410071111))	CEANALD		
2.						
3. 4.						
5.	<u> </u>					
I hereby claim the benefit under T	itle 35, United St	ates Code §119(e) of an	y United States provisional appl	ication(s) listed below:		
Application No.	,		(MM/DD/YYYY)	.,,		
1. 60/495,325 08/15/2003						
2						
3.		I				

DECLARATION FOR "371" APPLICATION Page 2 of 2

COMBINED DECLARATION FOR UTILITY or DESIGN	
PATENT APPLICATION WITH POWER OF ATTORNEY CON	tinued

FAMILY NAME

SPECTOR

Signature

Durham

POST OFFICE ADDRESS

GlaxoSmithKline

Five Moore Drive, PO Box 13398

CITY

FULL NAME

OF INVENTOR

INVENTOR'S

SIGNATURE

RESIDENCE &

CITIZENSHIP

POST OFFICE

ADDRESS

2

0

2

ATTORNEY'S DOCKET NUMBER PR60446USw

SECOND GIVEN NAME/INITIAL

COUNTRY OF CITIZENSHIP

STATE & ZIP CODE/COUNTRY

North Carolina 27709, US

Lee

US

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States

	is material to patent	application in the manner provide ability as defined in 37 C.F.R. § ing date of this application:	ded by the first 1.56 which beca	paragraph of 35 U.S.C. §112, ame available between the filin	I acknow g date of	ledge the duty to discl the prior application(s	ose information which and the national or
PRIOR	U.S. PARENT	APPLICATION or PCT	PARENT A	PPLICATION			
						STATUS (Check of	one)
U.S.	Parent Application or Number		Parent Filing D (MM/DD/YYY			PENDING	ABANDONED
POWE	R OF ATTORNEY	: As a named inventor, I here	ehy annoint th	ne practitioners associated u	with the (Customer Numbers	provided below to
prosecut	e this application an	d to transact all business in the d Customer Number 20462	he Patent and	Trademark Office connecte	d therev	vith	provided below to
Address	s all corresponden	ce and telephone calls to C	Customer No	umber 23347		Direct Telephone Ca	lls to:
	David J. Levy				Ì		
	Corporate Intellect	ual Property				Virginia Campen 919-483-1012	
	GlaxoSmithKline	DO D. 12200				717-463-1012	
	Five Moore Drive,	PO Box 13398 Park, NC 27709-3398			Ì	·	
I hereby				1.1 1.1 .			
ore beli	avad ta ba tava an	tatements made herein of r	ny own knov	wledge are true and that a	ill stater	nents made on int	ormation and belief
are being	eved to be true; ar	nd further that these statem	ents were m	ade with the knowledge t	hat will	ful false statement	ts and the like so
made ai	re punishable by fi	ne or imprisonment, or bo	th, under 18	U.S.C. 1001, and that su	ich wills	ful false statement	s may jeopardize
the vali	dity of the applica	tion or any patent issuing t	thereon.				
	FULL NAME	FAMILY NAME		FIRST GIVEN NAME		SECOND GIVEN NAME	ЛNITIAL
2	OF INVENTOR	BACUS		Sarah		S	
	INVENTOR'S	Signature	10			Date; A 1	<u>.</u>
	SIGNATURE	San	me	?			04
0	RESIDENCE &	CITY Hinsesdale		STATE OR FOREIGN COUNTRY		COUNTRY OF CITIZEN	ISHIP
	CITIZENSHIP POST OFFICE	POST OFFICE ADDRESS		CITY		US	A I IN I TO THE
1	ADDRESS	1222 Indian Trail		Hinsdale		STATE & ZIP CODE/CO	

FIRST GIVEN NAME

STATE OR FOREIGN COUNTRY

Research Triangle Park

Neil

NC

Doc Code:

PTO/SB/81 (04-05)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/US2005/02634	
Filing Date	August 10, 2004	
First Named Inventor	Sarah S. Bacus	
Title	BIOMARKERS IN CANCER	
Art Unit		
Examiner Name		
Attorney Docket Number	PR60446USw	

I here	by revoke all r	previou	us powers of attorney given in the a	above-iden	tified applica	ation.	
l here	I hereby appoint:						
\boxtimes	Practitione	Practitioners associated with the Customer Number:				23347	
	OR			L			
	Practitione	∍r(s) na	amed below:				
			Name		Regis	stration Numb	er
			gent(s) to prosecute the applicatior Trademark Office connected therev		above, and	to transact al	l business in the
Plea	ase recognize	or cha	nge the correspondence address for	for the abo	ve-identified	application to) :
\boxtimes	The address	associ	iated with the above-mentioned Cu	ustomer Nu	ımber:		
OR					1811		
	The address	associ	iated with Customer Number:				
OR							
	Firm or Individual Name	е					
Addres	ss						
City				State		Z	ip
Countr	у						
Teleph	ione			Email			
I am t	٠.	tor					
	Applicant/Invent						
	Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).						
			SIGNATURE of Applica	ant or Ass	ignee of Re	cord	//
Signat	ure		() Color			Date	62/4/206
Name		Charl	les E. Dadswell			Telephone	(919) 483-6983
	nd Company	Attorn	•		· · · · · · · · · · · · · · · · · · ·		
NOTE: multipl		all the	inventors or assignees of record of the	the entire in	terest or their	r representative	e(s) are required. Submit
-	Total of		forms are submitted.				

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc Code:

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	70 0-8-C	77 3 45 500 000	ind Oillib	COMITOT HU	TIDEI.
STATEMENT UNDER 37 C	IMIGNO DAG	a more mark	4 4	=	
		HI HEH OUT HE WILL B	- 1 N		266
		અ ગ ₩ 8// 11 11 €	_1	FFR	Z (!! ! !
	IER 3 73(b)				FAA

Applicant/Patent Owner: SmithKline Beecham Corporation				
	Filed/legue Deter have with			
Application No./Patent No./Control No.:	Filed/Issue Date: herewith_			
Entitled: BIOMARKERS IN CANCER				
SmithKline Beecham Corporation , a corporation	n			
(Name of Assignee) (Type of Assignee,	e.g., corporation, partnership, university, government agency, etc.)			
states that it is:				
1. the assignee of the entire right, title, and interest; or				
2. an assignee of less than the entire right, title and interest The extent (by percentage) of its ownership interest is	%			
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent ider States Patent and Trademark Office at	_			
OR				
B. A chain of title from the inventor(s), of the patent application/patent iden	tified above, to the current assignee as follows:			
1. From: To:				
The document was recorded in the United States Patent and Trademark (Reel , Frame , or for which a copy				
2. From: To: To: To: To: The document was recorded in the United States Patent and Trademark (Office at			
Reel , Frame , or for which a copy	thereof is attached.			
3. From: To:				
The document was recorded in the United States Patent and Trademark (Reel , Frame , or for which a copy				
Additional documents in the chain of title are listed on a supplemental				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document to the copy of the original assignment to the copy of the original assignment document to the copy of the original assignment to the copy of the original assignment document to the copy of the original assignment to the copy of the original assignment to the copy of the original assignment to the copy of the original assignme	t(s)) must be submitted to Assignment Division in			
Signature	Date			
Charles E. Dadswell	(919) 483-6983			
Printed or Typed Name Telephone number				
Attorney				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Power of Attorney

BY THIS POWER OF ATTORNEY given this 23rd day of February two thousand and five SMITHKLINE BEECHAM CORPORATION, a company incorporated in Pennsylvania (Registration No. 3330395) and having its registered office at One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America, (hereinafter called "the Company"), HEREBY appoints all and any of its Directors, Secretary and Assistant Secretary for the time being, and DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRRELL, HUGH BAINFORDE DAWSON, WENDY ANNE FILLER, MICHAEL JOHN STOTT, PETER I. DOLTON, HELEN KAYE QUILLIN, MARCUS JONATHAN WILLIAM DALTON, CHARLES M. KINZIG, STEPHEN VENETIANER, THEODORE R. FURMAN, MARY E. McCARTHY, EDWARD R. GIMMI, CHARLES EDWARD DADSWELL, ROBERT H. BRINK, and FRANK P. GRASSLER jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

- In any country or countries or jurisdiction in any part of the world to make application
 or cause application to be made for the grant or issue or transfer to the Company or
 registration in its name of Intellectual Property Rights and to take all steps necessary
 for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended
 or extended.
- 2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
- 3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sublicences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
- 4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the coexistence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
- 5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.

- 6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent, including trademark and patent agents and attorneys, to act on behalf of the Company.
- To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
- 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
- 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.
- 10. This Power of Attorney shall expire on December 31, 2006

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained

AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof SMITHKLINE BEECHAM CORPORATION has caused its Common Seal to be hereunto affixed the day and year first before written

The COMMON SEAL of SMITHKLINE BEECHAM CORPORATION was hereto affixed in the presence of:

Donald F. Parman

Vice President and Secretary